Skip to main content
Figure 1 | Cardiovascular Diabetology

Figure 1

From: Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

Figure 1

Incidence rate ratios for saxagliptin vs control (point estimates and 95% CI) for MACE in the 20-study pool, the saxagliptin 2.5- and 5-mg subanalysis, and the add-on to metformin study pool. Numbers in parentheses are total patient-years of exposure (the time up to an event or censoring). IRR = incidence rate ratio; MACE = major adverse cardiovascular events; MET = metformin; SAXA = saxagliptin.

Back to article page